bioAffinity closes ~$4.0M private placement: 8.46M pre-funded warrants + 2 companion warrants each
AI Summary
BioAffinity closed a private placement priced at-the-market raising approximately $4.0M by selling pre-funded warrants to purchase an aggregate 8,462,027 shares; each pre-funded warrant was issued with two common warrants and the combined unit price was $0.4657. The pre-funded warrants carry a $0.007 exercise price (immediate exercise possible upon holder action) and the companion warrants (≈16.9M total) have a $0.4727 exercise price, expire in five years and will be exercisable only following stockholder approval; underlying shares will dilute the cap table upon exercise/after approval. Timing: Warrant exercises are already completed, so dilution is already in effect.
Positives
- Gross proceeds of roughly $4.0M (before fees)
- Company will provide customary registration rights for shares underlying the warrants
Negatives
- Pre-funded warrants cover 8,462,027 shares plus two warrants per unit (~16.9M warrants) — material potential dilution (~25.4M instruments)
- Companion warrants become exercisable after stockholder approval, creating a delayed but significant overhang if approved
- Combined unit price ($0.4657) raised limited capital relative to potential share issuance
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: already triggered
Dilution status
live_now
Dilution timing
Dilution status: Immediate
Trigger type
already_triggered